TrialResults-center.org
Search
Menu
Home
Search
Recent trials
Browse pathology
Browse treatment
About us
Dalteparin
LMWH
systematic review
meta-analysis
network meta-analysis
Select
acute coronary syndrome
acute myocardial infarction
percutaneous coronary intervention
pulmonary embolism
thrombosis prevention
venous thrombosis
extended LMWH
extended prophylaxis
LMWH
long term LMWH
Low molecular weight heparin
once daily LMWH
short term LMWH
vs anticoagulant
vs heparin + anti Gp2b3a
vs oral anticoagulant
vs placebo or control
vs placebo or no treatment
vs Dextran
vs heparin
vs twice daily LMWH
vs UFH
vs Unfractionated heparin
vs unfractioned heparin
pdf
Filter
hide ongoing
show ongoing
hide ongoing
all ROB
Show all trials
Show only trial at low risk of bias
Hide exploratory trials
all results
Show all trials
Show only trial with conclusive result
Group by
Group by...
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
MA
in first
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in second
nothing
pathology
treatment
patient
comparator
classe
classe comparator
mechanism
clinical condition
in third
Description
Synopsis
Comparison
Treatments
Patients
Characteristics
Method
Risk of bias
References
None
Tools
Indexation
Results
Global trial result
Main results
All results
All result tag
NCT results
All cause death (38)
Major bleeding (32)
Bleeding (21)
Symptomatic venous thromboembolism (DVT, PE) (20)
asymptomatic DVT (19)
Symptomatic pulmonary embolism (19)
Minor bleeding (18)
wound haematoma / infection (14)
transfusion (14)
major or clinically relevant non-major bleeding (14)
total VTE and all-cause mortality (14)
Recurrent thromboembolic event (11)
myocardial infarction (fatal and non fatal) (7)
Short term haemorrhage (6)
Thrombus extension (6)
death, myocardial infarction, or recurrent at 30 days (5)
death at 30 days (5)
myocardial infarction at 30 days (5)
stroke (fatal and non fatal) (5)
myocardial infarction or death (5)
death, myocardial infarction, or recurrent at 14 days (5)
Revascularization (5)
recurrent angina (5)
Drop in platelet count of 50% (5)
Symptomatic deep-vein thrombosis (5)
fatal pulmonary embolism (5)
Venous thromboembolism (5)
net benefit (4)
proximal DVT (4)
Deep vein thrombosis (3)
pulmonary embolism (symptomatic and asymptomatic) (3)
distal DVT (3)
Deaths or MI (3)
reinfarction (3)
In-hospital death (3)
reinfarction at 30 days (3)
death at 30 days (3)
symptomatic venous thromboembolism at the end of treatment (2)
recurrent symptomatic venous thromboembolism and death at the end of treatment (2)
Recurrent Symptomatic Venous Thromboembolism or death (2)
proximal deep-vein thrombosis (2)
Venous thromboembolism or death (2)
Unplanned revascularisation for ischaemia (2)
VTE during active anticoagulant treatment (2)
VTE during follow-up after active anticoagulant treatment (2)
puylmonary embolism (2)
recurrent DVT (2)
MACE (2)
death, MI, unplanned revascularization (2)
non-fatal pulmonary embolism (1)
Recurrent DVT/DVT extension (symptomatic) (1)
Fatal bleeding (1)
Thrombocytopenia (1)
Long term death (1)
recurrent VTE (1)
death at 3 months (1)
Options
Numeric
bar chart
forest plot
medians
Trial
Studied trt
Control trt
patients
tags
ROB
Trial result
All cause death
Major bleeding
acute coronary syndrome
FRISC (long term), 1996
dalteparin
placebo (on top of aspirin)
Low risk of bias
suggesting
-15%
FRISC (short term), 1996
dalteparin
placebo (on top of aspirin)
Low risk of bias
-
FRIC prolonged treatment phase (LWMH vs PBO), 1997
dalteparin
placebo (on top of aspirin)
Low risk of bias
negative
61%
FRIC (acute phase LMWH vs UFH), 1997
dalteparin
UFH (on top of aspirin)
Exploratory
negative
257%
acute myocardial infarction
BIOMACS II, 1999
Dalteparin
placebo
Low risk of bias
-
FRAMI, 1997
Dalteparin
placebo
-
ASSENT Plus, 2003
Dalteparin
UFH
negative
percutaneous coronary intervention
Natarajan (without antiGp2b3a), 2003
dalteparin
UFH
-
Natarajan (+ antiGp2b3a), 2003
dalteparin
UFH + anti Gp2b3a
-
pulmonary embolism
Kuijer, 1995
Dalteparin
unfractionated heparin
negative
Meyer, 1995
Dalteparin
unfractionated heparin
negative
thrombosis prevention
Lapidus, 2007
dalteparin
placebo
Low risk of bias
negative
Lapidus, 2007
dalteparin
placebo
Low risk of bias
negative
D-KAf (Selby), 2007
NCT
dalteparin
placebo
negative
Leizorovicz, 2004
dalteparin
placebo
medical patients
Low risk of bias
suggesting
2%
∞%
Jorgensen, 1989
dalteparin
placebo
hip surgery
Low risk of bias
suggesting
-100%
Torholm, 1991
dalteparin
placebo
hip surgery
Low risk of bias
suggesting
∞%
Ockelford , 1989
dalteparin
placebo
suggesting
-100%
-7%
Matzsch , 1991
dalteparin
Dextran
hip surgery
suggesting
Eriksson , 1988
dalteparin
Dextran
hip surgery
suggesting
Matzsch , 1988
dalteparin
Dextran
hip surgery
negative
Lassen, 1998
out of hospital Dalteparin
standard prophylaxis
negative
-100%
Dahl, 1997
out of hospital Dalteparin
standard prophylaxis
suggesting
-2%
Hull, 2000
out of hospital Dalteparin
standard prophylaxis
suggesting
-100%
PROTECT, 2011
NCT
dalteparin
UFH
medical patients
Low risk of bias
suggesting
-10%
-2%
Scala, 1990
dalteparin
UFH
Risk of bias
negative
-5%
Haas , 1985
dalteparin
Unfractionated heparin
hip surgery
negative
Binsack , 1986
dalteparin
Unfractionated heparin
hip surgery
negative
Barre , 1987
dalteparin
Unfractionated heparin
hip surgery
negative
Dechavanne , 1989
dalteparin
Unfractionated heparin
hip surgery
negative
Eriksson , 1989
dalteparin
Unfractionated heparin
hip surgery
suggesting
-100%
Monreal , 1989
dalteparin
Unfractionated heparin
hip surgery
negative
-36%
Creperio, 1990
dalteparin
unfractionated heparin
general surgery
negative
Hartl, 1990
dalteparin
unfractionated heparin
abdominal surgery
suggesting
48%
-34%
Borstad, 1992
dalteparin
unfractionated heparin
gynaecological surgery
-
Fricker, 1988
dalteparin
unfractionated heparin
abdominal surgery
negative
100%
Koller, 1986
dalteparin
unfractionated heparin
abdominal surgery
negative
∞%
Koller, 1986
dalteparin
unfractionated heparin
abdominal surgery
negative
161%
Onarheim, 1986
dalteparin
unfractionated heparin
abdominal surgery
negative
8%
Bergqvist, 1988
dalteparin
unfractionated heparin
abdominal surgery
negative
-2%
Bergqvist, 1986
dalteparin
unfractionated heparin
abdominal surgery
negative
236%
Caen, 1988
dalteparin
unfractionated heparin
abdominal surgery
negative
-35%
-100%
Borstad, 1988
dalteparin
unfractionated heparin
gynaecological surgery
negative
5%
Briel, 1988
dalteparin
unfractionated heparin
non orthopedic surgery
negative
Kakkar, 1993
dalteparin
unfractionated heparin
abdominal surgery
-
venous thrombosis
CLOT (Lee), 2003
extended dalteparin
standard treatment
suggesting
-4%
57%
Das, 1996
Dalteparin
warfarin
Risk of bias
negative
Lee, 2003
Dalteparin
warfarin
Risk of bias
suggesting
Holmström, 1992
once daily dalteparin
twice daily dalteparin
negative
Partsch, 1996
once daily dalteparin
twice daily dalteparin
negative
153%
Holm et al , 1986
Dalteparin
unfractionated heparin
negative
Bratt et al, 1990
Dalteparin
unfractionated heparin
negative
83%
Lindmarker et al , 1993
Dalteparin
unfractionated heparin
negative
-32%
Bratt et al , 1985
Dalteparin
unfractionated heparin
negative
×
Modal title